NCT05384262 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

June 14, 2024

Study Completion Date

June 14, 2024

Conditions

Dyslipidemia

Interventions

DRUG

AZD0780

Subjects will receive AZD0780 orally as a single ascending dose.

DRUG

AZD0780

Subjects will receive AZD0780 orally as a multiple ascending dose.

DRUG

AZD0780

Subjects will receive AZD0780 orally as a single and multiple ascending dose.

DRUG

Placebo

Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

DRUG

Placebo

Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

DRUG

Placebo

Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.

DRUG

Rosuvastatin

Subjects will receive rosuvastatin orally.

Trial Locations (3)

Research Site, Brooklyn

Research Site, Glendale

Research Site, Harrow